BSD Medical Reports Significant Quarterly Growth of MicroThermX® Microwave Ablation System Sales and Equipment Utilization

  BSD Medical Reports Significant Quarterly Growth of MicroThermX® Microwave
  Ablation System Sales and Equipment Utilization

Business Wire

SALT LAKE CITY -- December 06, 2012

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems utilizing heat therapy to treat cancer,
announced today a 586% increase in sales for the MicroThermX^® Microwave
Ablation System (MicroThermX^®) product line for the fiscal quarter ended
November 30, 2012, as compared to the fiscal quarter ended November 30, 2011.
Disposable SynchroWave antennas were a significant portion of these sales,
reflecting the success of the Company's fee-per-use equipment rental program
and increasing sales of MicroThermX^® equipment. This is a dramatic increase
in sales for MicroThermX^® products and representative of a continuing trend
of accelerating MicroThermX^® revenue.

BSD's current focus is to increase MicroThermX^® revenues by expanding the
fee-per-use equipment rental program and increasing direct sales support in
major U.S. metropolitan areas. These programs continue to produce very
successful results, and the current fiscal year promises to provide continuing
growth in revenues from the MicroThermX^® products. The MicroThermX^®
introduced into the Company’s product line an innovative, high-end disposable
that is used in each ablation treatment, providing an important ongoing
revenue stream.

About the MicroThermX^® Microwave Ablation System

The MicroThermX^® Microwave Ablation System is a compact, mobile,
state-of-the-art, proprietary system that includes a microwave generator,
single-patient-use disposable antennas, and a thermistor-based temperature
monitoring system. The innovative design of the MicroThermX^® is the first of
its kind that allows delivery of higher power levels using a single generator.
The MicroThermX^® utilizes innovative synchronous phased array technology that
was developed and patented by BSD to provide larger and more uniform zones of
ablation during a single procedure. The MicroThermX^® introduces into the
Company’s product line an innovative, high-end disposable that is used in each
ablation treatment, and will provide a significant ongoing revenue stream. The
soft tissue ablation world market potential is estimated to exceed $2.3
billion. The U.S. Food and Drug Administration (FDA) has granted the Company a
510(k) clearance to market the MicroThermX^® for ablation of soft tissue. BSD
has also received CE Marking for the MicroThermX^® System, which allows BSD to
market the MicroThermX^® system in Europe. CE Marking is also recognized in
many countries outside of the EU, providing BSD the ability to market the
MicroThermX^® to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to ablate and destroy soft tissue. The Company has
developed extensive intellectual property, multiple products in the market and
well established distribution in the United States, Europe and Asia. Certain
of the Company’s products have received regulatory approvals in the United
States, Europe and China. For further information visit BSD Medical's website
at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.

Contact:

BSD Medical Corporation
Dennis Gauger
Telephone: (801) 972-5555
Facsimile: (801) 972-5930
Email: investor@bsdmc.com
 
Press spacebar to pause and continue. Press esc to stop.